ENGLEWOOD, Colo., Feb. 21, 2018 Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today provided an update on the ongoing launch of Natesto in the U.S. Robust Natesto prescription growth continued through January 2018, with total prescriptions reaching 1,094, their highest level to date and demonstrating 300% growth over the same month last year. Additionally, for the three months ending January 31, 2018 Natesto prescriptions increased 12% over the three-month period ending October 31, 2017.

The Company reports the following prescription and prescriber growth for the one-month and three-month periods ending January 31, 2018:

• Natesto total prescriptions for the month of January were 1,094, the highest monthly total recorded to date. New prescriptions for Natesto for the month of January increased to 758.
• Prescribers of Natesto in the month of January totaled 405, representing a 4% increase over December’s prescriber count.
• Natesto total prescriptions were 3,051 for the three-month period ending January 31, 2018, representing a 12% increase over the three-month period ending October 31, 2017.

Josh Disbrow, Chief Executive Officer of Aytu BioScience commented, “Aytu is increasing adoption of Natesto at a rapid rate, and the Company is pleased with the sustained positive acceptance by physicians and patients. The dual strengths of a highly differentiated product profile and a sales force becoming progressively more experienced at selling the product, has resulted in all-time highs for Natesto in terms of both prescription levels and prescribers. We remain enthusiastic about the uptake of Natesto, particularly the robust increase over these past 90 days.”

Mr. Disbrow continued, “With the February 2018 launch of the Natesto Support Program, a new initiative aimed at increasing both new and refill prescription rates at retail pharmacies, we expect to further accelerate the growth of Natesto.”

The Company expects to continue to provide periodic updates on the ongoing launch of Natesto in the U.S.

About Aytu BioScience, Inc.

Aytu BioScience is a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology, with a focus on products addressing vitality, sexual wellness, and reproductive health. The Company currently markets two prescription products in the U.S.: Natesto®, the first and only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or “Low T”) and ProstaScint® (capromab pendetide), the only FDA-approved imaging agent specific to prostate specific membrane antigen (PSMA) for prostate cancer detection and staging. Additionally, Aytu is developing MiOXSYS®, a novel, rapid semen analysis system with the potential to become a standard of care for the diagnosis and management of male infertility caused by oxidative stress. MiOXSYS® is commercialized outside the U.S. where it is a CE Marked, Health Canada cleared, Australian TGA approved product, and Aytu is planning U.S.-based clinical trials in pursuit of 510k medical device clearance by the FDA. Aytu’s strategy is to continue building its portfolio of revenue-generating products, leveraging its focused commercial team and expertise to build leading brands within growing markets. For more information visit aytubio.com. Aytu also now wholly-owns its subsidiary Aytu Women’s Health (formerly Nuelle, Inc.), a personal health and wellness company focused on women’s sexual wellbeing and intimacy. Aytu Women’s Health markets Fiera, a personal care product for women that is scientifically proven to enhance physical arousal and sexual desire. Fiera is a consumer product and is not intended to treat, mitigate, or cure any disease or medical condition. For more information about the Fiera personal care device visit fiera.com.

Forward Looking Statement

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this presentation, including statements regarding our anticipated future clinical and regulatory events, future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. Forward looking statements are generally written in the future tense and/or are preceded by words such as “may,” “will,” “should,” “forecast,” “could,” “expect,” “suggest,” “believe,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: risks relating to gaining market acceptance of our products, the continued growth of prescriptions and prescribers of Natesto, obtaining reimbursement by third-party payors, the potential future commercialization of our product candidates, the anticipated start dates, durations and completion dates, as well as the potential future results, of our ongoing and future clinical trials, the anticipated designs of our future clinical trials, anticipated future regulatory submissions and events, our anticipated future cash position and future events under our current and potential future collaborations. We also refer you to the risks described in “Risk Factors” in Part I, Item 1A of Aytu BioScience, Inc.’s Annual Report on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time.

Contact for Investors:

James Carbonara
Hayden IR
(646)-755-7412
james@haydenir.com

View original content with multimedia:http://www.prnewswire.com/news-releases/aytu-bioscience-provides-update-on-the-continued-growth-of-natesto-in-the-us-300601652.html

SOURCE Aytu BioScience, Inc.